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Invited Commentary
IMPORTANCE COVID-19 is a life-threatening illness for many patients. Prior studies have
established hematologic cancers as a risk factor associated with particularly poor
outcomes from COVID-19. To our knowledge, no studies have established a beneficial role
for anti–COVID-19 interventions in this at-risk population. Convalescent plasma therapy
may benefit immunocompromised individuals with COVID-19, including those with
hematologic cancers.

Supplemental content

OBJECTIVE To evaluate the association of convalescent plasma treatment with 30-day

mortality in hospitalized adults with hematologic cancers and COVID-19 from a
multi-institutional cohort.
DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study using data from
the COVID-19 and Cancer Consortium registry with propensity score matching evaluated
patients with hematologic cancers who were hospitalized for COVID-19. Data were collected
between March 17, 2020, and January 21, 2021.
EXPOSURES Convalescent plasma treatment at any time during hospitalization.
MAIN OUTCOMES AND MEASURES The main outcome was 30-day all-cause mortality. Cox
proportional hazards regression analysis with adjustment for potential confounders was
performed. Hazard ratios (HRs) are reported with 95% CIs. Secondary subgroup analyses
were conducted on patients with severe COVID-19 who required mechanical ventilatory
support and/or intensive care unit admission.
RESULTS A total of 966 individuals (mean [SD] age, 65 [15] years; 539 [55.8%] male) were
evaluated in this study; 143 convalescent plasma recipients were compared with 823
untreated control patients. After adjustment for potential confounding factors, convalescent
plasma treatment was associated with improved 30-day mortality (HR, 0.60; 95% CI,
0.37-0.97). This association remained significant after propensity score matching (HR, 0.52;
95% CI, 0.29-0.92). Among the 338 patients admitted to the intensive care unit, mortality
was significantly lower in convalescent plasma recipients compared with nonrecipients
(HR for propensity score–matched comparison, 0.40; 95% CI, 0.20-0.80). Among the
227 patients who required mechanical ventilatory support, mortality was significantly
lower in convalescent plasma recipients compared with nonrecipients (HR for propensity
score–matched comparison, 0.32; 95% CI, 0.14-0.72).
CONCLUSIONS AND RELEVANCE The findings of this cohort study suggest a potential survival
benefit in the administration of convalescent plasma to patients with hematologic cancers
and COVID-19.
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S

ince initial reports in late 2019, SARS-CoV-2 has infected more than 100 million people worldwide and
caused more than 2 million deaths by early 2021.1 To
date, data guiding COVID-19 therapies have largely arisen from
large-scale studies2,3 of healthy adults. Patients with hematologic cancers represent a distinctive subset of patients with
COVID-19 caused by immune deficits associated with both
the diseases themselves and their treatments. Hematologic
cancers have been consistently associated with increased
COVID-19 mortality and other complications.4-6
Antibody-based immunity is an important correlate of
SARS-CoV-2 recovery and vaccine-associated prevention.
Hematologic cancers are associated with defects in humoral
and cellular immunity that may contribute to adverse COVID-19
outcomes. Impaired antibody function is a well-described complication of plasma cell neoplasms, chronic lymphocytic leukemia (CLL), and other lymphoid cancers. Treatment of hematologic cancers often exacerbates these immune defects; for
example, rituximab targets the pan-B cell marker CD20 and is
highly effective therapy for B-cell cancers. However, B-cell
depletion can cause lymphopenia and hypogammaglobulinemia and is associated with more severe COVID-19.7 Lymphopenia is known to be associated with more severe COVID-19.8
Antibody therapy using COVID-19 convalescent plasma was
associated with a therapeutic benefit in a general patient
population9 and older patients10 when high titer units were administered early in the disease. A negative prospective randomized trial included only 4 patients with hematologic cancers in the convalescent plasma group.11 In patients with
immunodeficiency, case reports have noted exceptional improvements in clinical status after convalescent plasma therapy,
even after relatively late infusion.12 Given the absence of definitive prospective trial data in patients with hematologic cancers, we conducted a retrospective cohort study to evaluate
the hypothesis that convalescent plasma therapy can correct
defects in humoral deficiency and improve outcomes.

Methods
Setting and Participants
The COVID-19 and Cancer Consortium (CCC19) is an international consortium aimed at understanding the clinical impact of COVID-19 in patients with cancer through a Vanderbilt University Institutional Review Board–exempted
comprehensive registry. The methods for CCC19 have been
described and published previously.13 We analyzed data from
hospitalized US adults with a current or past diagnosis of hematologic cancers diagnosed with confirmed or suspected
SARS-CoV-2 infection in 2020 and reported from March 17,
2020, to January 21, 2021 (full list of contributors is in the
eAppendix in Supplement 1). Treatment exposure was defined as receiving convalescent plasma at any time during the
COVID-19 illness. The exclusion criteria were incomplete follow-up resulting in unknown death status, unknown or missing convalescent plasma exposure, age younger than 18 years,
mild COVID-19 not requiring hospitalization, and non-US residence. The following data elements were obtained: age, sex,
E2
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Key Points
Question Is convalescent plasma therapy associated with
improved outcomes of hospitalized patients with COVID-19 and
hematologic cancer?
Findings In this cohort study of 966 patients with hematologic
cancer and COVID-19, after adjustment for potential confounding
factors, convalescent plasma treatment was associated with
a significantly improved 30-day mortality in the 143 individuals
who received it. This association remained significant after
propensity score matching.
Meaning These findings suggest a potential survival benefit
in the administration of convalescent plasma to patients with
hematologic cancers and COVID-19.

race and ethnic groups, smoking status, comorbidities, the first
recorded absolute lymphocyte count, type of hematologic
cancer, cancer status at COVID-19 diagnosis, Eastern Cooperative Oncology Group (ECOG) performance status before
COVID-19, receipt and timing of anticancer treatment, baseline COVID-19 severity, level of care required, other anti–
COVID-19 therapies (ie, corticosteroids, remdesivir, tocilizumab, and hydroxychloroquine), and US Census region of
patient's residence. Race and ethnic groups were as reported
in the electronic health record of the patients and were included because of numerous reports of racial and ethnic disparities in patients with COVID-19. The Vanderbilt University
Institutional Review Board determined that informed consent was not required, and all data were deidentified. The full
data dictionary is provided in eTable 1 in Supplement 1. This
study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Statistical Analysis
We calculated bivariate frequencies to examine the associations among the baseline characteristics and receipt of convalescent plasma. The primary end point was death within 30
days of COVID-19 diagnosis. Living patients had their data censored at 30 days from diagnosis. Crude and adjusted hazard
ratios (HRs) and 95% CIs to estimate the association between
convalescent plasma use and 30-day all-cause mortality were
calculated using Cox proportional hazards regression models. The primary analysis used propensity score matching to
help account for the nonrandomized treatment administration of convalescent plasma.14 Individual propensities for receipt of convalescent plasma treatment were estimated using
a multivariable probit regression model with baseline covariate adjustment using covariates that were determined a priori
based on published literature and clinical importance: age, sex,
race and ethnic groups, hematologic cancer type, cancer
status, cancer treatment timing, ECOG performance status,
obesity, presence of type 2 diabetes, hypertension, renal comorbidities, pulmonary comorbidities, receipt of cytotoxic chemotherapy within 3 months of COVID-19 diagnosis, and trimester of diagnosis (January to April 2020, May to August
2020, or September to December 2020). For matching, the
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nearest-neighbor method with a 1:1 ratio (treated units to control units) and 0.2 SD of the distance measure was applied to
estimate the mean treatment effect.15 Marginal HRs along with
95% CIs based on cluster-robust SEs are reported. KaplanMeier survival curves were generated to compare survival probabilities using log-rank and stratified log-rank tests between
convalescent plasma recipients and nonrecipients for unmatched and matched samples, respectively. We conducted
several sensitivity analyses to explore the robustness of the
findings for the primary hypothesis against the model specifications, such as varying the caliper size by ±0.1 and changing the matching order from the default maximum distance
first to random order with different seeds. Exploratory subgroup analyses were conducted to determine whether patients with more severe illness (intensive care unit admission
and/or mechanical ventilatory support) had differential outcome by convalescent plasma exposure.
We interpreted findings based on the 95% CIs for the estimated measures of association. Reported P values are 2-sided,
with α < .05 considered to be statistically significant. Statistical analyses were performed using R software, version 4.0.3
with packages MatchIt and Survival (R Foundation for Statistical Computing).

Results
As of January 21, 2021, the CCC19 registry contained 8209 case
reports with complete baseline information. A total of 1761 patients (21.5%) had a primary or secondary hematologic cancer,
with lymphoid cancers being the most common. After eligibility criteria were applied (eFigure 1 in Supplement 1), 966
patients (mean [SD] age, 65 [15] years; 539 [55.8%] male) were
available for evaluation, of whom 143 (14.8%) received convalescent plasma treatment and 823 were untreated control patients (eFigure 2 in Supplement 1). Key patient characteristics
are noted in Table 1; additional characteristics, including type
of blood cancer and stage at cancer diagnosis, are provided in
eTable 2 in Supplement 1. In the unmatched sample, convalescent plasma recipients were slightly younger and more likely to
be male. A lower proportion of convalescent plasma recipients
had pulmonary comorbidities and ECOG performance status of
2 or higher compared with the unexposed group. Convalescent plasma recipients were also more likely to be treated with
corticosteroids, tocilizumab, and/or remdesivir and less likely
to be treated with hydroxychloroquine. Overall, 512 patients
(53.0%) had received systemic anticancer treatment within
3 months of COVID-19 diagnosis, with targeted therapies (monoclonal antibodies, small molecule inhibitors, and/or immunomodulators) being the most commonly received treatments.
A total of 115 (22.5%) of those treated received an anti-CD20
antibody–containing regimen. Overall, 489 of 845 patients
(57.9%) with an absolute lymphocyte count available had lymphopenia (lymphocyte count, <1500/μL [to convert to ×109/L,
multiply by 0.001]) at presentation; this proportion increased
to 91 (79.1%) in patients who had received anti-CD20 antibodies. Propensity score matching was successful, with good balance achieved between the exposed and nonexposed groups
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(eFigures 3-5 in Supplement 1). The matched nonexposed group
of 143 patients had more patients with multiple myeloma
(47 [32.9%] vs 31 [21.7%]), fewer patients with CLL (12 [8.4%]
vs 27 [18.9%]), and lower rates of disseminated disease at cancer diagnosis (100 [69.9%] vs 114 [79.7%]). Convalescent plasma
recipients were more likely to require aggressive care (with
76 [53.1%] requiring intensive care unit admission and 45
[31.5%] requiring mechanical ventilatory support). Bleeding,
sepsis, pulmonary complications, and congestive heart failure were more frequent in convalescent plasma recipients, with
bleeding complications occurring in 16 (11.2%) convalescent
plasma recipients vs 6 (4.2%) in propensity score–matched control patients, sepsis complications in 58 (40.6%) convalescent plasma recipients vs 32 (22.4%) propensity score–
matched control patients, respiratory failure in 99 (69.2%)
convalescent plasma recipients vs 66 (46.2%), and congestive heart failure in 10 (7%) convalescent plasma recipients vs
fewer than 5 (<3.5%; entries other than missing or unknown
with fewer than 5 patients were masked per CCC19 policy).
Rates of hepatic and kidney injury were similar in both groups
(8 [5.6%] of convalescent plasma recipients vs 7 [4.9%] of propensity score–matched control patients had acute hepatic injury and 37 [25.9%] of convalescent plasma recipients vs 39
[27.5%] of propensity score–matched control patients had acute
kidney injury) (Table 2). Rates of venous thrombosis (15 [10.5%]
vs 12 [8.4%]), arterial thrombotic events (5 [3.5%] vs <5
[<3.5%]), and arrhythmias (5 [3.5%] vs <5 [<3.5%]) were low
and comparable in the convalescent plasma recipients vs the
propensity score–matched controls.
With a median follow-up period of 30 days (interquartile
range, 21-90 days), 223 (23.1%) deaths occurred within 30 days
of COVID-19 diagnosis (Table 3). The crude mortality rate was
significantly lower in convalescent plasma recipients (19 of 143
[13.3%]) compared with nonrecipients (204 of 823 [24.8%]).
This difference was statistically significant after adjustment
in the overall comparison (HR, 0.60; 95% CI, 0.37-0.97; P = .03)
and the propensity score–matched comparison (HR, 0.52; 95%
CI, 0.29-0.92; P = .03) (Table 3 and Figure). Multiple additional sensitivity analyses, including analyses that used different caliper sizes for matching and analyses with randomized matching orders, found similar results. Among the 338
patients admitted to the intensive care unit, the crude mortality rate was significantly lower in convalescent plasma recipients compared with nonrecipients in the overall comparison (adjusted HR, 0.30; 95% CI, 0.16-0.56) and the propensity
score–matched comparison (HR, 0.40; 95% CI, 0.20-0.80).
Among the 227 patients requiring mechanical ventilatory support, the crude mortality rate was significantly lower in convalescent plasma recipients compared with nonrecipients in
the overall comparison (HR, 0.23; 95% CI, 0.10-0.50) and the
propensity score–matched comparison (HR, 0.32; 95% CI, 0.140.72) (Table 3; eFigure 6 in Supplement 1).

Discussion
This cohort study adds to the accumulating evidence supporting the efficacy of convalescent plasma treatment in patients
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Table 1. Characteristics of Patients Receiving or Not Receiving CP Before and After Propensity Score Matchinga
Unmatched patients

Propensity score–matched patients

CP
(n = 143)

No CP
(n = 823)

CP
(n = 143)

No CP
(n = 143)

4 (1-8)

NA

4 (1-8)

NA

18-39

12 (8.4)

54 (6.6)

12 (8.4)

15 (10.5)

40-59

37 (25.9)

174 (21.1)

37 (25.9)

38 (26.6)

60-69

45 (31.5)

233 (28.3)

45 (31.5)

45 (31.5)

70-79

31 (21.7)

209 (25.4)

31 (21.7)

28 (19.6)

≥80

18 (12.6)

153 (18.6)

18 (12.6)

17 (11.9)

Male

82 (57.3)

457 (55.5)

82 (57.3)

85 (59.4)

Female

61 (42.7)

366 (44.5)

61 (42.7)

58 (40.6)

White

81 (56.6)

413 (50.2)

81 (56.6)

73 (51.0)

Black

19 (13.3)

174 (21.1)

19 (13.3)

29 (20.3)

Hispanic

26 (18.2)

152 (18.5)

26 (18.2)

24 (16.8)

Other

16 (11.2)

70 (8.5)

16 (11.2)

13 (9.1)

Missing or unknown

1 (0.7)

14 (1.7)

1 (0.7)

4 (2.8)

Hypertension

80 (55.9)

485 (58.9)

80 (55.9)

75 (52.4)

Obesity

53 (37.1)

282 (34.3)

53 (37.1)

53 (37.1)

Diabetes

38 (26.6)

259 (31.5)

38 (26.6)

41 (28.7)

Pulmonary

19 (13.3)

191 (23.2)

19 (13.3)

19 (13.3)

Renal

32 (22.4)

182 (22.1)

32 (22.4)

31 (21.7)

0

37 (25.9)

196 (23.8)

37 (25.9)

40 (28.0)

1

53 (37.1)

267 (32.4)

53 (37.1)

57 (39.9)

≥2

17 (11.9)

172 (20.9)

17 (11.9)

15 (10.5)

Unknown

36 (25.2)

188 (22.8)

36 (25.2)

31 (21.7)

Mild

25 (16.9)

147 (17.9)

25 (16.9)

29 (20.3)

Moderate

79 (55.6)

503 (61.1)

79 (55.6)

87 (60.8)

Severe

34 (23.9)

166 (20.2)

34 (23.9)

24 (16.8)

Missing or unknown

5 (3.5)

7 (0.9)

5 (3.5)

3 (2.1)

Hospitalizationc

142 (99.3)

823 (100)

142 (99.3)

143 (100)

ICU admission

76 (53.1)

262 (31.8)

76 (53.1)

41 (28.7)

Mechanical ventilatory support

45 (31.5)

182 (22.1)

45 (31.5)

29 (20.3)

Corticosteroid

79 (55.2)

229 (27.8)

79 (55.2)

44 (30.8)

Remdesivir

72 (50.3)

153 (18.6)

72 (50.3)

35 (24.5)

Hydroxychloroquine

34 (23.8)

272 (33.0)

34 (23.8)

42 (29.4)

Tocilizumab

19 (13.3)

54 (6.6)

19 (13.3)

8 (5.6)

Lymphoid

123 (86.0)

642 (78.0)

123 (86.0)

130 (90.9)

Myeloid

21 (14.7)

185 (22.5)

21 (14.7)

12 (8.4)

Characteristic
Time between hospitalization
and first CP, median (IQR), db
Age group, y

Sex

Race and ethnic group
Non-Hispanic

Comorbidity

ECOG performance status

Baseline COVID-19 severity

Abbreviations: CP, convalescent
plasma; ECOG, Eastern Cooperative
Oncology Group; ICU, intensive care
unit; IQR, interquartile range; NA, not
applicable.
a

Data are presented as number
(percentage) of patients unless
otherwise indicated.

b

Timing information was not initially
available and was collected from
sites after analysis. Information was
collected for 107 of 143 (74.8%) of
cases. For these cases, median time
from COVID-19 diagnosis to first
CP administration was 6.5 days
(IQR, 2-14 days). Median time
from COVID-19 diagnosis to first
hospitalization was 0 days
(IQR, 0-3 days).

c

Hospitalization status could not be
verified for 1 patient receiving
convalescent plasma; given that this
treatment is given nearly universally
in the hospital setting, the patient
was retained for analysis.

d

Percentages total to more than
100% because some patients had
multiple hematologic cancers
(synchronous or metachronous).

Level of care required

Other medications received
during COVID-19 illness

Type of hematologic cancerd

Cancer status

E4

Remission

45 (31.5)

251 (30.5)

45 (31.5)

50 (35.0)

Stable or responding

59 (41.3)

339 (41.2)

59 (41.3)

54 (37.8)

Progressing

18 (12.6)

125 (15.2)

18 (12.6)

13 (9.1)

Unknown

21 (14.7)

108 (13.1)

21 (14.7)

26 (18.2)
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Table 2. Selected Complications in CP Recipients, Propensity Score–Matched Control Patients,
and All Control Patients
No. (%) of patients

CP recipients
(n = 143)

No CP
Propensity
score–matched
control patients
(n = 143)

Venous thromboembolism

15 (10.5)

12 (8.4)

63 (7.7)

Myocardial infarction and/or
cerebrovascular accident
Congestive heart failure

5 (3.5)

<5 (<3.5)a

26 (3.2)

10 (7)

<5 (<3.5)a

45 (5.5)

Arrhythmia complications

5 (3.5)

<5 (<3.5)a

27 (3.3)

Complication
Cardiovascular complications

Unmatched
control patients
(n = 823)

Pulmonary complications
Respiratory failure

99 (69.2)

66 (46.2)

398 (48.4)

Pneumonia and/or pneumonitis

78 (54.5)

61 (42.7)

299 (36.3)

Acute respiratory distress syndrome

38 (26.6)

12 (8.4)

114 (13.9)

Bleeding complications

16 (11.2)

6 (4.2)

47 (5.7)

Sepsis complications

58 (40.6)

32 (22.4)

187 (22.7)

Acute hepatic injury

8 (5.6)

7 (4.9)

41 (5)

Acute kidney injury

37 (25.9)

39 (27.3)

222 (27)

Other complications

with primary or secondary immunodeficiency, including those
subjected to profound immunosuppression in the setting of
hematopoietic stem cell transplantation.16,17 Patients with
hematologic cancers may have immunodeficiencies from
patient factors (including age), disease factors, and treatment factors. For example, in a single-center cohort of patients with CLL who had documented symptomatic COVID19, 7 of 21 (33%) did not develop detectable anti–SARS-CoV-2
antibodies, notably lower than the 100% seroconversion rate
observed in a noncancer population.18,19 A larger study20
recently found lower rates of seroconversion in patients with
hematologic cancers, patients who received anti-CD20 antibodies, and hematopoietic transplant recipients. Several small
studies21-23 have found improvement in clinical course after
administration of convalescent plasma to patients with cancer, primarily hematologic cancers. Clinical improvement in
COVID-19 symptoms within 48 hours of convalescent plasma
transfusion was also reported in 16 of 17 patients with B-cell
lymphopenia and prolonged COVID-19, 15 of whom had received anti-CD20 therapy in the 3 to 6 months before symptom onset.23
There is historical evidence of the efficacy of passive antibody therapy for infectious diseases when given early in the
disease before the development of endogenous antibody responses, including in severe acute respiratory infections.24-26
On this basis, interventional trials of convalescent plasma treatment for patients with COVID-19 are ongoing; to our knowledge, only one of these, COVID19-Convalescent Plasma for
Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID),27 is specifically recruiting patients with
cancer. Despite this notable absence of prospective clinical trials
specifically for patients with cancer, there was widespread
availability of convalescent plasma through the Expanded
Access Program (EAP) and the subsequent US Food and Drug
Administration Emergency Use Authorization (EUA). The EAP

Abbreviation: CP, convalescent
plasma.
a

Entries other than missing or
unknown with fewer than 5 patients
are masked per COVID-19 and
Cancer Consortium policy.

Table 3. Association Between Convalescent Plasma Use
and Death Within the Crude Analysis, Multivariable Analysis,
and Propensity Score Analyses
Variable
Overall population
No. of events/No. of patients at risk (%)

HR (95% CI) for death
within 30 days
223/966 (23.1)

Convalescent plasma

19/143 (13.3)

No convalescent plasma

204/823 (24.8)

Crude analysisa

0.47 (0.30-0.76)

Multivariable analysisb

0.60 (0.37-0.97)

Propensity score matchingc

0.52 (0.29-0.92)

Subgroup requiring ICU admission
No. of events/No. of patients at risk (%)

135/338 (39.9)

Convalescent plasma

12/76 (15.8)

No convalescent plasma

123/262 (46.9)

Crude analysisa

0.26 (0.14-0.47)

Multivariable analysisb

0.30 (0.16-0.56)

Propensity score matchingc

0.40 (0.20-0.80)

Subgroup requiring mechanical ventilatory support
No. of events/No. of patients at risk (%)

105/227 (46.3)

Convalescent plasma

8/45 (17.8)

No convalescent plasma

97/182 (53.3)

Crude analysisa

0.24 (0.16-0.49)

Multivariable analysisb

0.23 (0.10-0.50)

Propensity score matchingc

0.32 (0.14-0.72)

Abbreviations: ICU, intensive care unit; HR, hazard ratio.
a

The HRs from the bivariable model in all patients from the unmatched study
cohort.

b

The HRs form the multivariable stratified Cox proportional hazards regression
model, with stratification by trimester of diagnosis with additional covariate
adjustment.

c

Marginal HRs from propensity score–matched sample, constructed using 1:1
nearest neighbor matching with calipers of width equal to 0.2 of the SD of the
distance measure.

jamaoncology.com

Downloaded From: https://jamanetwork.com/ by a Henry Ford Health System User on 07/21/2021

(Reprinted) JAMA Oncology Published online June 17, 2021

E5

Research Original Investigation

Survival in Patients With Hematologic Cancers and COVID-19

Figure. Overall Survival Rates Among Recipients vs Nonrecipients of Convalescent Plasma
A Overall comparison

B

Recipients of convalescent plasma

1.0

Overall survival probability

1.0

Overall survival probability

Propensity score-matched comparison

Recipients of convalescent plasma

0.8
Nonrecipients of convalescent plasma
0.6
0.4
0.2

Log-rank test P <.001
0

0.8
Nonrecipients of convalescent plasma
0.6
0.4
0.2

Stratified log-rank test P =.004
0

0
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20

0

30

10

20

30
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was open to more than 2800 acute care facilities in the US
and territories.28 Presumably, most patients in this report received treatment through the EAP, EUA, or local non–cancerspecific clinical trials.
Lymphopenia was common in the study population, especially in patients with recent anti-CD20 treatment, as would
be expected. We are unable to ascertain rates of hypogammaglobulinemia because this was not a routinely collected variable. The exact mechanism by which convalescent plasma may
have mediated improved outcomes in the treated patients is
likely multifactorial and could include reduction in viral load
via enhanced clearance,23 reduction in secondary bacterial
and fungal infections, neutralization of inflammatory cytokines that may otherwise promote a hyperinflammatory
immune phenotype, 29 and temporizing until the native
immune system generates additional humoral and cellmediated responses in the recovery phase after myelosuppressive or lymphodepleting anticancer therapy.
The current study is the largest such series reported to date,
to our knowledge. Because of the multi-institutional nature
of the data with more than 70 contributing institutions (eAppendix in Supplement 1), these findings are unlikely to be the
result of specific practice patterns at certain institutions. Variables collected through this effort, such as cancer status, prior
cancer treatments, and ECOG performance status, are not readily available through automated electronic health record
extractions or claims databases. Notably, despite superior survival in the convalescent plasma group, there were considerably more sepsis and respiratory complications in this group.
This finding likely reflects a higher severity of SARS-CoV-2
infection rather than complications from the treatment, although this possibility cannot be entirely excluded. Adverse
effects of protein-rich infusions can include thromboses,
kidney injury, and volume overload.30-32 It is reassuring that
the rates of thromboses are low in both recipients and nonrecipients and the rates of acute kidney injury are similar.
Although low, the rate of congestive heart failure in the convalescent plasma recipients is higher than in the matched
E6

Nonrecipients of
convalescent plasma 143
Recipients of
convalescent plasma 143

control patients, and this finding bears additional scrutiny in
larger cohorts.

Limitations
This study has limitations, including its retrospective nature
and unmeasured variables, such as the exact timing of convalescent plasma administration with respect to the date of
COVID-19 diagnosis, the antibody titers and levels in the
plasma that was administered, and whether repeat dosing
was used. Although timing information is valuable, the feasibility of creating and maintaining a large, primarily voluntary, registry effort has necessitated study design decisions
that would minimize the data entry burden for respondents;
temporality is particularly burdensome and is only collected
for very limited events (eg, death). As with many pharmacoepidemiological studies, immortal time bias is possible for
both the time to convalescent plasma exposure in the treatment group and time from COVID-19 diagnosis to hospitalization in both recipients and nonrecipients.33 The registry
data also lack details on timing and sequence of other treatment exposures in relation to convalescent plasma administration. Despite propensity matching, it is possible that
residual confounding remains, and results should be interpreted with caution. For example, even after propensity
matching, the convalescent plasma recipients received more
corticosteroids and remdesivir. Although these agents have
not been found to have a clear survival benefit in cancer
populations,34 it is possible that at least part of the observed
protective effect of convalescent plasma could be attributable to concomitant medications, including fewer administrations of hydroxychloroquine. There are some notable
differences in blood cancer type and stage between the
recipients and matched control patients, all of which would
be expected to lead to worse outcomes in the recipients,
where in fact the opposite was observed. These differences
include more patients with multiple myeloma in the
matched control patients, who have an intermediate
prognosis.35-37 Conversely, more convalescent plasma recipi-
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ents had CLL, which has been assoc iated w ith poor
outcomes.38 Convalescent plasma nonrecipients may have
received less aggressive care overall because of factors other
than COVID-19 (eg, advanced states of cancer); this possibility is partially addressed through adjustment for cancer status. In addition, fewer patients in the convalescent plasma–
therapy group had disseminated disease at cancer diagnosis.
Differential access to convalescent plasma because of health
care system or socioeconomic factors, similar to what we previously observed for the investigational drug remdesivir, cannot be excluded.34 Although multi-institutional diversity is
a strength of our study, it is also likely that heterogeneity in
how stressed or overloaded a hospital was when the patient
with COVID-19 was treated, as well as differences in academic and community settings, could have added additional
potential confounding. It is possible that the findings in the
first 30 days would not persist into later periods, which would
require a more extended follow-up. Therefore, as with any
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observational study, causality cannot be inferred from these
findings, but rather these findings can be viewed as contributing to the accumulating evidence regarding survival benefit with convalescent plasma treatment in patients with
COVID-19 illness. Prospective randomized trials evaluating
convalescent plasma in patients with hematologic cancers with
attention to administration timing and consideration of
repeated dosing are recommended.

Conclusions
This cohort study found that convalescent plasma therapy was
associated with a survival benefit in patients with hematologic cancers and COVID-19. If this finding should hold
up in prospective clinical trials, convalescent plasma would
be, to our knowledge, the first COVID-19 intervention with
a survival benefit in this high-risk population.
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